2021 Revenues ($USD) : $19,400,000,000
2021 R&D spend : $155,000,000
2021 Number of Employees : na
Fiscal Year End : 12/31/2021
Leader : CEO Yin Weidong

Thanks to its CoronaVac COVID-19 vaccine, Sinovac saw 38 times more revenue in 2021 than the year before. Its revenues last year were $19.4 billion. As of April 2022, it had provided 2.8 billion doses of CoronaVac worldwide. The company projects that its vaccine sales will fall as the pandemic wanes. While the COVID-19 vaccine has stoked sales, the vaccine appears to not be as effective as mRNA-based vaccines. A study from the University of Hong Kong found that three doses of the CoronaVac vaccine failed to "provide adequate levels" of protection against infection from the omicron variant. In 2021, Sinovac also won Chinese regulatory approval for its Sabin inactivated polio vaccine (sIPV). Other products in the company’s lineup include Inlive (enterovirus 71 vaccine), Anflu (influenza vaccine), Healive (hepatitis A vaccine), varicella vaccine and mumps vaccine. —BB